Pharmaron Acquires 82.54% of Biortus Biosciences

AVS Bio Acquires Biorbyt Ltd.

September 23, 2026

Biotechnology

AVS Bio, a portfolio company of Arlington Capital Partners, acquired Biorbyt Ltd., a supplier of life-science research reagents and biomaterials. The acquisition expands AVS Bio’s product catalog, global distribution capabilities, and ecommerce offering; Biorbyt will continue operating under its existing leadership as part of the AVS Bio platform.

Merck KGaA to Acquire Bio-Techne for $11.3 Billion

June 25, 2026

Healthcare Services

Merck KGaA has entered a definitive agreement to acquire Bio-Techne for $73 per share in an all-cash transaction valued at about $11.3 billion (enterprise value). The deal is expected to close in late 2026 or early 2027, subject to regulatory approvals and Bio-Techne shareholder approval.

Bruker Corporation Acquires biocrates life sciences ag

June 3, 2025

Biotechnology

Bruker Corporation has acquired biocrates life sciences ag, an Innsbruck, Austria-based leader in mass-spectrometry-based quantitative metabolomics. The deal adds biocrates' metabolomics kits, assays, software and contract research services to Bruker's multiomics strategy, expanding Bruker's MS-based metabolomics and integrated multiomics capabilities. Financial terms were not disclosed.

BioNTech Acquires Biotheus

February 3, 2025

Biotechnology

BioNTech SE has completed the acquisition of clinical-stage biotechnology company Biotheus for $800 million in cash and ADS consideration plus up to $150 million in milestone payments. The deal gives BioNTech full global rights to BNT327 and Biotheus' antibody platform, and adds a local R&D hub and biologics manufacturing facility in China to BioNTech's network to support its oncology strategy.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

Pharmaron Acquires Absorption Systems

November 9, 2020

Healthcare Services

Pharmaron Beijing Co., Limited acquired 100% of Absorption Systems for up to US$137.5 million in cash. The purchase brings Absorption Systems’ non-clinical DMPK/ADME and bioanalysis capabilities and U.S. lab footprint (Philadelphia, San Diego and Boston) into Pharmaron’s integrated drug R&D services platform to expand capabilities and U.S. presence.